HPV Testing and Pap Test Market is expected to reach a valuation of US$ 15 Billion by 2032 | FMI

 The Global HPV testing and Pap Test Market was valued at US$ 2.2 Billion in 2021 and is expected to reach US$ 15 Billion by 2032, finds Future Market Insights (FMI) in a recent market survey. As per the findings of the report, Pap Testing will remain pivotal for the market as the bulk of revenue will be generated through this category, with a forecasted CAGR of 17.5%.


Official strategies and policies, such as the WHO global strategy for cervical cancer elimination, are expected to boost demand for testing. New technologies, government programs, and awareness drives will help boost demand in even low-resource areas.

For more information @ https://www.futuremarketinsights.com/reports/hpv-testing-and-pap-test-market

Cervical Cancer Screening to Continue being the key application for HPV and Pap Test Revenue

Vaginal Cancer cannot be detected with a Pap or HPV tests on their own. They can, however detect cervical cancer and HPV, and pre-cancerous conditions. This is useful since the presence of these can be precursors to cervical cancer.

The US to Command the Larger Proportion of HPV testing and Pap test consumption in the Analysis Period

The US contributed the most to the demand for HPV and Pap Tests. The ACS recommends screening women over 25 at recommended intervals of time. There are also programs that provide free or cheaper testing to women such as the NBCCEDP by the CDC.

HPV testing and Pap Test Market: Competition Insights

HPV Testing and Pap Test providers are focused on increasing the efficiency, accuracy and affordability of their tests and harnessing new technology. The key companies operating include Abbott Laboratories, Qiagen N.V., Becton, Dickinson and Company, Quest Diagnostics, Inc., Hologic, Inc., F. Hoffmann-La Roche, Femasys, Inc., Arbor Vita Corporation, NURX, Inc., Seegene, Inc., Thermo Fisher Scientific. Inc., bioMérieux SA

Some of the recent developments in HPV Testing and Pap Test are as follows:

  • In June 2022, Hoffmann-La Roche AG, a Switzerland-based healthcare pharmaceutical and diagnostics company announced the launch of a self-sampling solution, via which patients can collect samples privately at a healthcare facility under instructions and have them analyzed. The aim of enabling self-collection was to provide an alternative to the usual invasive clinician-based collection process.
  • In May 2022, Alercell, Inc, a molecular diagnostics company and provider of diagnostics announced it’s HPV DNA based test kit: "Meltpro HPV genotype test". It is based on DNA sequencing analysis. The use of a PCR machine eliminates the risk of human interpretation and provides faster results, taking under three hours.
  • In June 2022, Operating in the oncology healthcare sector, Karkinos Healthcare developed CerviRaksha, a clinically validated HPV test, pre-qualified and approved by the World Health Organization (WHO) and the United States Food and Drug Administration (FDA). It was also granted the CE mark and bears the CE mark. Samples are collected at home and results are provided by email. The HPV-16 and HPV-18 genotypes are distinguished individually, and false positives are filtered.
  • In May 2022, The London School of Hygiene and Tropical Medicine and the University of Manchester, and the University of Hull will collaborate to test for cervical cancer in women of the 65-and-older age group, who are often overlooked despite accounting for over 50% of cervical cancer incidents in the UK. This test will also only require a urine sample, which might encourage women who were opting out of the test to take part.

Full Information Source @ https://www.futuremarketinsights.com/reports/hpv-testing-and-pap-test-market

Key Segments Covered in HPV Testing and Pap Test Survey

HPV Testing and Pap Test Market by Type:

  • HPV Testing
  • Pap Test

HPV Testing and Pap Test Market by Application:

  • Vaginal Cancer Screening
  • Cervical Cancer Screening

HPV Testing and Pap Test Market by Product Type:

  • Instruments
  • Consumables
  • Services

HPV Testing and Pap Test Market by Technology:

  • PCR
  • Immunodiagnostics
  • Other Technologies

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more